Anti-FGF23 treatment was found to significantly improve the bone quality in CKD mice by correcting the secondary hyperparathyroidism, and increased calcitriol levels, indicating that FGF23 is a key factor of CKD related bone diseases. The gene discussed is FGF23; the disease is chronic kidney disease.